AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01097122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forearm vibration
Description: Mechanical loading with forearm vibration will be applied right radius in all groups
Study NCT01477164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity aerobic exercise
Description: Participants will perform 12-weeks of high intensity aerobic training. Training will be 5-days per week. Three days (e.g. Monday, Wednesday and Friday) will include repeated bouts of cycling for 4-minutes at \~90% maximal effort followed by 3 minutes of active rest. The other two days (e.g. Tuesday and Thursday) will be treadmill exercise for 45 minutes at 70% of maximal effort.
Study NCT01255163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Placebo SC twice daily
Study NCT01477164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: Participants will perform 12-weeks of resistance exercise training. Training will be 5-days per week of daily sessions of 60 minutes that include resistance exercise for all major muscle groups.
Study NCT01477164 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined
Description: The combined group will be assessed before and after 12 weeks of no exercise training, then again following 12 weeks of combined aerobic and resistance exercise training.
Study NCT01367197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: group based exercise training
Study NCT00297427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture twice weekly for 6 weeks.
Study NCT00297427 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Twice a week for 6 weeks
Study NCT01572168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Eight session of weekly acupuncture
Study NCT03927339 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: pre and post excercise group
Description: Treadmill Training Protocol~Each eligible participant in the patients group was then prospectively assigned to undergo exercise session of full-body-free weight treadmill training. Once the participants were prepped, they performed stretching for 5 min and slow walking for 3 min as a warm-up exercise before starting the training. Stretch was carried out similarly to all the subjects to quadriceps femoris and the hamstring. In the warm-up time period , it was enforced for 3 min at the speed of1 km/h. Then patients began the walking trials and walked at 1 to 1.34 m/s on an electric car treadmill (JACO fitness: JACO-212C).
Study NCT03462173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: yimitasvir
Description: Capsule administered orally once daily
Study NCT03462173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching Placebo Capsule
Study NCT04512703 — intervention group
Intervention type: DEVICE
Intervention: µCor
Description: Sensor Monitor for arrhythmia and other bio-metric markers
Study NCT03856489 — intervention group
Intervention type: OTHER
Intervention: Richards-Campbell Sleeping Questionnaire (RCSQ)
Description: This five-item visual analogue scale was designed as an outcome measure for assessing the perception of sleep in critically ill patients. The scale evaluates perceptions of depth of sleep, sleep onset latency, number of awakenings, time spent awake, and overall sleep quality.
Study NCT00058253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV
Study NCT00058253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT03080935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Subjects will receive Evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.
Study NCT02577640 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy bread
Description: Soy breads will be produced using a sponge-dough process. Finished dough will be formed, panned, and proofed in proofing cabinet (\~95% RH) at 40ºC for 60 minutes. Proofed loaves will be baked for 50 minutes at 150ºC in a convection oven (jet air oven, model: JA14, Doyon, Liniere, Quebec, Canada). Breads will be considered done at an internal temperature of 95 ± 5ºC.
Study NCT02295644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Sonicator 740
Description: Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1MHz, 5 minutes
Study NCT00838071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Specific intravenous anti-hepatitis B immunoglobulin
Description: Monthly doses of 5000 IU administered intravenously during 6 consecutive months
Study NCT00943345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: indometacin
Description: * capsule for oral consumption~* at 22h00 evening before test day: 75 mg~* at 7h30 on the test day: 50 mg This intervention will be applied 4 times (4 arms).
Study NCT00943345 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: indometacin
Description: * capsule for oral consumption~* at 22h00 evening before test day: 75 mg~* at 7h30 on the test day: 50 mg This intervention will be applied 4 times (4 arms).
Study NCT01692119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular, pharmacy based intervention
Description: Regular, pharmacy-based intervention conducted in cooperation with the treating physician:~* Medication review at baseline: recording of all medicines currently taken (prescribed medication and self-medication), check for drug-related problems, consolidation of a medication plan.~* Regularly (weekly): dose-dispensing of the medication (weekly dosing aid), discussion and counseling regarding medication, adherence, potential side effects, and signs and symptoms of cardiac decompensation; blood pressure and pulse measurement. If required: contact with patients' physician.
Study NCT03585270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazosentan
Description: Clazosentan will be administered as a continuous intravenous infusion at the dose of 15 mg/hour for up to 14 days.
Study NCT03585270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered at the same infusion rate as clazosentan for up to 14 days.
Study NCT03472053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO-11006 plus standard of care
Description: BIO-11006 is administered 125mg BID plus standard of care.
Study NCT03472053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Pemetrexed (500 mg/meter square) and Carboplatin (AUC6, Calvert's formula) are administered every three weeks for three months.
Study NCT00569101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: during the first 2 months : tacrolimus 0.1 mg/kg + prednisolone 0.8 mg/kg p.o. ,then after : tacrolimus 0.1 mg \~0.02 mg/kg + prednisolone tapering
Study NCT01717222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal Lignocaine
Description: Patients will receive 100 ml of 0.2% lignocaine
Study NCT04500249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infiltration rescue intraoperative analgesia
Description: in the case of intraoperative pain perception, rescue infiltration analgesia using 1 % lidocaine administered by the operator into the operation field.
Study NCT04500249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rescue IA
Description: in the case of intraoperative pain perception, rescue intravenous analgesia using 50 mcg of fentanyl will be administered by anaesthesiologist
Study NCT04500249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rescue antyhypertensive medication
Description: in the case of intraoperative hypertension reluctant to rescue analgesia, rescue intravenous antihypertensive medication using 10 mcg of urapidil will be administered by anaesthesiologist
Study NCT04500249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rescue antyemetic medication
Description: in the case of postoperative nausea and vomitting, rescue intravenous antiemetic medication using 4 mg of ondansetron will be administered by anaesthesiologist
Study NCT04500249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rescue antyhypotensive medication
Description: in the case of intraoperative hypotension, rescue intravenous antihypotensive medication using 10 mg of ephedrine will be administered by anaesthesiologist
Study NCT04500249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rescue antyhypotensive medication
Description: in the case of intraoperative bradycardia, rescue intravenous antihypotensive medication using 500 mcg of atropine will be administered by anaesthesiologist
Study NCT01717222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Lignocaine
Description: Intravenous group patients will receive 1.5mg/kg of lignocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion until one hour after surgery
Study NCT02756910 — intervention group
Intervention type: DEVICE
Intervention: iThermonitor (WT701)
Description: Continuously monitor the axillary temperature during surgery
Study NCT02093949 — intervention group
Intervention type: PROCEDURE
Intervention: Routine substrate ablation without pulmonary vein Isolation
Study NCT02093949 — intervention group
Intervention type: PROCEDURE
Intervention: Routine conventional ablation with pulmonary vein Isolation
Study NCT03475654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-assisted rehabilitation
Description: The Jintronix software platform, coupled with the Microsoft Kinect for movement capture, contains individualized exercise modules to increase ROM, endurance and strength. Within this PRCT, online monitoring of activity and actigraphy measurements through a wearable device and completion of an online diary will provide enhanced monitoring of home activities.
Study NCT03475654 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The control group will receive treatment as usual, which includes a personalized home exercise program prescribed by a burn therapist, prior to hospital discharge.
Study NCT03914001 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: mpMRI
Description: all eligible patients will undergo mpMRI 4 weks after initial TURBT
Study NCT03914001 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Second look TURBT
Description: after mpMRI all patients will subjected to second look TURBT
Study NCT01202097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone
Study NCT01202097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide
Study NCT04035278 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengusiil
Description: Dengusiil is provided as lyophilized powder to be reconstituted with 0.5 mL sterile water for injection (sWFI).The reconstituted vaccine is injected as a single 0.5 mL subcutaneous (SC) dose.
Study NCT04035278 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is supplied as a vial of lyophilized powder containing all the components of the vaccine except dengue virus serotypes (DENV1, 2, 3 and 4) to be reconstituted with 0.5 mL sterile water for injection (sWFI).The reconstituted product is injected as a single 0.5 mL subcutaneous (SC) dose.
Study NCT03126669 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric oxygen
Description: Breathing 100% oxygen at 2ATA in the hyperbaric chamber
Study NCT03126669 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Hyperbaric chamber, normal air
Description: Hyperbaric chamber with normal air
Study NCT01953705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3 PUFA
Description: fish oil concentrate standardized to long chain n-3 PUFA content
Study NCT01953705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02048475 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: desflurane
Description: changing concentration
Study NCT02908295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rectal Misoprostol
Description: Rectal Misoprostol Misoprostol 400 mcg (200 mcg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
Study NCT02908295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rectal Vitamin B6 Vitamin B6 (Placebo) 200 mg (100 mg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
Study NCT02570204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-assessment
Description: Patients enrolled into the study will do a multi-level pregnancy test (MLPT) at enrollment, and will receive one MLPT to do at home one week after taking mifepristone and misoprostol. They will be instructed to call the study site if the at-home MLPT result do not decline, or if they experience any abortion complications.
Study NCT00022659 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00022659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03167242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAF156
Description: KAF156 comes in 100 mg tablets for oral administration. KAF156 was administered in combination with LUM-SDF once daily (QD) for 1, 2 or 3 days at 200 mg, 400 mg or 800 mg doses.
Study NCT03889704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnistim® FX²
Description: The Omnistim® FX² is a neuromuscular stimulation device that provides patterned electrical neuromuscular stimulation (PENS) via cutaneous electrodes placed over relevant musculature. The device mimics physiologic patterns of neuron firing.
Study NCT01757197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toclizumab
Description: 8 mg/kg IV, once every 1-2 weeks. The maximum dose per infusion should not exceed 800 mg.
Study NCT04439162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: retrograde cardioplegia protection
Description: antegrade-retrograde cardioplegia
Study NCT04365023 — intervention group
Intervention type: DRUG
Intervention: platinum chemotherapy
Description: First line platinum chemotherapy
Study NCT02569593 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Iron supplements, more specific Ferrodyn and Vista Ferrum
Description: Ferrodyn is an Fe-chelate supplement. One tablet contains 28 mg elemental iron. Vista Ferrum is an iron(II)sulfate supplement. One tablet also contains 28 mg elemental iron. The volunteers will be asked to take the provided supplement orally with 150 mL of water.
Study NCT01603901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Regulated Negative Pressure-Assisted Wound Therapy Device
Description: Negative pressure will be applied in the usual way that is normally applied in our Medical Center
Study NCT00436852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-751
Description: Given orally
Study NCT00436852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00823576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Compare the evolution of the postoperative levels of pain until J2, in the scheduled lumbar surgery between 2 groups of patients, one receiving a single bolus of analgesic, one receiving a single bolus of analgesic and an infiltration of Ropivacaine during 48 hours.
Study NCT05141240 — intervention group
Intervention type: DRUG
Intervention: Ribiciclib
Description: Participants who initiated CDK4/6i therapy
Study NCT05141240 — intervention group
Intervention type: DRUG
Intervention: Palbociclib
Description: Participants who initiated CDK4/6i therapy
Study NCT05141240 — intervention group
Intervention type: DRUG
Intervention: Abemaciclib
Description: Participants who initiated CDK4/6i therapy
Study NCT02940587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aurix
Description: Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
Study NCT02580305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUVN-502
Description: Once-daily, tablets, orally
Study NCT02580305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily, tablets, orally
Study NCT02580305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Donepezil HCl (10 mg, once a day)
Study NCT02580305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: Donepezil HCl (10 mg, once a day)
Study NCT02580305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Memantine HCl (10 mg, twice a day or 28 mg extended-release, once a day).
Study NCT02580305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Memantine
Description: Memantine HCl (10 mg, twice a day or 28 mg extended-release, once a day).
Study NCT02370927 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Non pulse extruded cereal
Study NCT02370927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea protein
Description: Pulse extruded cereal
Study NCT02370927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea Starch
Description: Pulse extruded cereal
Study NCT02370927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea fibre + pea starch
Description: Pulse extruded cereal
Study NCT02370927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea protein + pea starch
Description: Pulse extruded cereal
Study NCT02370927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea fibre + pea starch + pea protein
Description: Pulse extruded cereal
Study NCT01955967 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine
Study NCT03167242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coartem
Description: Coartem comes as 20/120 mg dispersible tablets or 80/480 mg tablets for oral administration. Coartem was administered twice daily for 3 days as active comparator.
Study NCT02507453 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: parabolic flight
Study NCT02507453 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: mass/weight perception estimation
Description: estimate the mass/weight perception, expressed by verbally report the absolute and relative mass of the object using a scale from 1 to 10 (1 being light and 10 being heavy)
Study NCT02507453 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ESA short-arm human centrifuge (SAHC)
Study NCT03818724 — intervention group
Intervention type: DEVICE
Intervention: CoolLoop® cryoablation system
Description: Cryoablation of Atrial Fibrillation using the CoolLoop® Cryoablation System
Study NCT04343287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BRM421
Description: The active control with BRM421 solution
Study NCT04343287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The vehicle solution
Study NCT01800734 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clamp-Mixed Meal Arm
Description: Standard clinical parameters will be assessed in all patients.~Metabolic tests:~A. Euglycemic insulin clamp. A standard euglycemic insulin clamp will be carried out to assess insulin sensitivity, as previously described (1).~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter. Right before meal ingestion, a s.c. fast insulin analogue bolus will be administered by the pump~This test will determine the time courses of:~1. plasma glucose, 2.13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal.
Study NCT00833768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer carbonate
Description: 800mg tablets to be taken orally with meals three times per day
Study NCT00833768 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for sevelamer carbonate
Description: Placebo tablets to be taken orally with meals three times per day
Study NCT04183036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoclip papillaplasty
Description: Endoclip papilloplasty was performed to repair the Oddi sphincter using sterile repositionable hemostasis clipping device (Micro-tech (Nanjing), Co., Ltd.; stainless-steel). The operator positioned the clip and assessed the clip position and made sure the incision was clipped. Four to five endoclips were positioned in the incision in a zipper way from distal to proximal papillary sphincterotomy
Study NCT02842762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Right ventricular epicardial pacing
Description: The patient's own heart rate at that moment will be the starting point for the study. Right ventricle pacing will be instituted by selecting a rate that is 5 beats above the patient's own heart rate. We will use a stepwise approach where we increase the pacermaker's rate with steps of 5 beats until we have 100% capture of the pacemaker beats. After waiting for at least one minute of pacing we will obtain a set of measurements.
Study NCT02842762 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: cardiac surgery
Description: Elective cardiac surgery, with use of cardiopulmonary bypass.